A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?» Read More
Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.
CNBC's Meg Tirrell, and Daniel O'Day, Roche Pharmaceuticals COO, talk about the the encouraging results in treating lung cancer and using precision medicines to personalize treatment.
CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Texas is forgoing about $100 billion in federal funds by not expanding a major health program for the poor.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
Meg Tirrell tells us why the future of cancer therapy may almost be here.
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
Health insurer Humana has received takeover interest, with potential bidders including Aetna and Cigna, according to reports.
As the government program reaches the half-century mark, it needs to get into the digital age, says this University of Rochester professor.
Congressional Republicans have yet to act on plans to deal with the potential loss of subsidies for HealthCare.gov customers.
Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
When it comes to planning for long-term health-care costs, the rich are a lot like most Americans—they haven't given it much thought.
Health care giant Johnson & Johnson has formally accepted a $1.94 billion offer to sell its Cordis heart devices unit to Cardinal Health.
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
The Affordable Care Act will add $273.6 billion in insurance administrative overhead costs from 2012 to 2022, a new report says.
Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.
Jawbone is suing Fitbit and a group of employees who quit Jawbone, saying they stole trade secrets, business plans, and market research.
Get the best of CNBC in your inbox